Account Info
Log Out
English
Back
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh Refresh
Loading
History record delete
    Quotes All >
      News All >
        Log in to access Online Inquiry
        Back to the Top

        Novo Nordisk Semaglutide/cardiovascular outcomes SELECT Trial Results

        Previously reported top-line results showed semaglutide 2.4 mg delivered a statistically significant 20% risk reduction in MACE over a period of up to five years versus placebo (HR: 0.80; 95% confidence interval: 0.72; 0.90, p<0.001). Today’s findings showed that risk reductions in MACE were achieved regardless of age, gender, ethnicity and starting body mass index (BMI).
        The results also demonstrated that the beneficial effects in MACE risk reduction were evident soon after treatment initiation, suggesting an effect that is more rapid than what would be expected if the cardiovascular effects were entirely mediated with the effects of semaglutide 2.4 mg on body weight reduction.1 This suggests that weight loss alone may not fully explain the benefits of semaglutide 2.4 mg in reducing the risk of MACE."$Novo-Nordisk A/S(NVO.US)$ $Eli Lilly and Co(LLY.US)$
        Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
        Translate
        Report
        8699 Views
        Comment
        Sign in to post a comment
          255Followers
          25Following
          777Visitors
          Follow